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This study is aimed at analysing biochemical and genetic endpoints of toxic effects after administration of adrenaline. For this
purpose, the study was carried out on Wistar rats and three doses of adrenaline were used: 0.75mg/kg, 1.5mg/kg, and 3mg/kg
body weight. To achieve these aims, we investigated the effects of adrenaline on catalase (CAT), Cu, Zn-superoxide dismutase
(SOD), malondialdehyde (MDA), nitrite (NO2−), carbonyl groups (PCC), and nitrotyrosine (3-NT). Total activity of lactate
dehydrogenase (LDH), its relative distribution (LDH1–LDH5) activity, level of acute phase proteins (APPs), and genotoxic effect
were also evaluated. The obtained results revealed that all doses of adrenaline induced a significant rise in CAT activity, MDA
level, PCC, NO2
−, and 3-NT and a significant decrease in SOD activity compared to control. Adrenaline exerted an increase in
total activity of LDH, LDH1, and LDH2 isoenzymes. Further study showed that adrenaline significantly decreased serum
albumin level and albumin-globulin ratio, while the level of APPs (α1-acid glycoprotein and haptoglobulin) is increased. The
micronucleus test revealed a genotoxic effect of adrenaline at higher concentrations (1.5mg/kg and 3mg/kg body weight)
compared to untreated rats. It can be concluded that adrenaline exerts oxidative and nitrative stress in rats, increased damage to
lipids and proteins, and damage of cardiomyocytes and cytogenetic damage. Obtained results may contribute to better
understanding of the toxicity of adrenaline with aims to preventing its harmful effects.
1. Introduction
Adrenaline (epinephrine) is a naturally occurring catechol-
amine which is secreted by the medulla of the adrenal glands.
As a drug, adrenaline was discovered over a century ago and
has been used in human cardiopulmonary resuscitation since
1922 [1]. Adrenaline also finds application in treatment of
cardiac arrest, asthma, allergic reactions, and glaucoma [2].
Adrenaline acts through the alpha and beta adrenergic recep-
tors which leads to vasoconstriction, an increase in the rate
and force of contraction of the heart, and dilatation of
bronchi and cerebral vessels. During normal physiological
conditions, there is no constant secretion of adrenaline, but
under the stress condition, a high level of adrenaline is
released to prepare body for “fight or flight” response [3].
However, adrenaline at other catecholamine at doses
exceeding physiological levels may cause toxic effects [4, 5].
There are studies indicating toxic effects of adrenaline via sig-
nal transduction pathways [6, 7]. Also, it seems that adrena-
line exerts detrimental effects via oxidative products of its
metabolism [8–10]. In line with this, it was shown that auto-
oxidation of catecholamine may generate reactive oxygen
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species (ROS) [11]. One of the final products of oxidative
metabolism-adrenochrome is able to stimulate oxidation of
adrenaline in which superoxide anion (O2
·−) and hydrogen
peroxide (H2O2) are formed. Besides, it was reported that
catalase and quercetin diminished the DNA-damaging effect
of adrenaline in vitro [12].
It is well known that overproduction of ROS can lead to
disruption of redox balance and cause oxidative stress [13].
Namely, if antioxidative mechanisms fail to remove excess
level of ROS, cells become prone to damage of DNA, pro-
teins, and lipids [14]. Proteins are among major targets of
ROS or reactive nitrogen species (RNS) and lead to changes
in protein content such as carbonyl group formation and
nitrotyrosine (3-NT) generation [15]. There are assumptions
that high level of adrenaline may cause protein damage via
free radicals [16]. It is worth noting that oxidative damage
to proteins plays an important role in loss of physiological
functions, thus favoring development of various diseases
[17–19]. On the other hand, lipid peroxidation by ROS may
initiate the peroxidation of membrane lipids and cause cellu-
lar injuries. In addition, oxidative DNA damages play a role
in the mutagenesis and an increased risk of tumors [20, 21].
Although there are indications that adrenaline could
increase the level of ROS, the cause-consequence relationship
between them is not fully understood. For this purpose, we
determined parameters of oxidative status: catalase (CAT)
Cu, Zn-superoxide dismutase (SOD), malondialdehyde
(MDA), nitrite (NO2
−), lactate dehydrogenase (LDH), and
carbonyl groups (PCC) after administration of adrenaline in
Wistar rats. Also, we evaluated how adrenaline influenced
the level of acute phase proteins (APPs), α1-acid glycoprotein
(AGP), haptoglobin (Hp), and level of 3-NT. Possible
genotoxic effects of adrenaline on bone marrow cells using
micronucleus test were also estimated. The results of this
investigation should contribute to a better understanding of
adrenaline toxicity with aims to preventing its harmful effects.
2. Materials and Methods
2.1. Animals. In this study, Wistar rats aged 18 weeks weigh-
ing 220–280 g were obtained from the Institute of Biomedical
Research, University of Belgrade. Three experimental groups
with adrenaline and two control groups (negative and posi-
tive) contained seven male Wistar rats. The animals were
kept under controlled constant environmental conditions
(25± 4°C, 55± 5% humidity) with a 12/12 h light/dark cycle.
They received food and water ad libitum. Care and animal
treatment were conducted according to the Guide for the
Care and Use of Laboratory Animals (National Research
Council [22]). The investigation was approved by the Ethical
Committee of the Faculty of Veterinary Medicine (University
of Belgrade).
2.2. Doses and Treatment. Three experimental doses of
adrenaline were used: 0.75mg/kg, 1.5mg/kg, and 3mg/kg
body weight, corresponding to 15%, 30%, and 60%, respec-
tively, of LD50 [23]. Cyclophosphamide was used as a posi-
tive control and 60mg/kg body weight per rats was given,
while the negative control group was treated with saline
(0.9% NaCl) [24]. The intraperitoneal (i.p.) route of applica-
tion was used in all experimental groups. After 24 hours of
treatments, all rats were euthanized. From each animal,
blood and bone marrow from both femurs were taken.
2.3. Blood Sampling. Blood samples for the biochemical
analysis were taken from the rats by puncture of v. jugularis
and collected into heparinized tubes. Plasma was obtained
from blood by centrifugation at 3000 rpm for 10min. Eryth-
rocytes were rinsed three times in isotonic solution of NaCl
(0.9%). Then, samples were frozen at −20°C until analysis.
Haemoglobin concentration was estimated by the cyano-
methaemoglobin method [25]. Haemolysates of erythrocytes
were used for determination of activities of antioxidant
enzymes (SOD, CAT) and level of MDA. Plasma was used
for determination of NO2
− concentration, 3-NT, protein car-
bonyl groups, total LDH level and its isoenzyme activity, and
levels of APPs, Hp, and AGP.
2.4. Oxidative Stress Parameters. The Cu, Zn-superoxide
dismutase (SOD) activity in erythrocytes was determined
spectrophotometrically according to Misra and Fridovich
[26] and expressed in units/gram of haemoglobin (U/g Hb).
The relative activity of SOD was determined by means of
vertical electrophoresis at 10% polyacrylamide gel electro-
phoresis (PAGE) and oxidation of nitro blue tetrazolium
(NBT) following the Beauchamp and Fridovich method
[27] (Hoeffer miniVE, Amersham, LKB, 2117, Bromma,
Uppsala, Sweden). The band intensity was measured using
TotalLab TL120, and results were expressed in arbitrary
U/g Hb.
Catalase (CAT) activity in erythrocytes was assayed by
means of the UV kinetic method at absorbance of 240nm
with the presence of H2O2 [28]. Activity was expressed as
U/g Hb, calculated by using an extinction coefficient of
39.4M−1 cm−1.
The level of malondialdehyde (MDA) in erythrocytes was
quantified by measuring the formation of thiobarbituric acid
reactive substances (TBARS) [29, 30]. The absorbance of the
colored MDA-TBARS complex was measured at a wave-
length of 535nm and expressed in nM MDA/g Hb.
Nitrite concentration (NO2
−) in plasma was determined
with Griess reagent [31] on a microplate reader at 540nm
(plate reader, Mod. A1, Nubenco Enterprises, ICN). The
results were expressed in μM.
The determination of carbonyl groups (PCC) was per-
formed spectrophotometrically with 2,4-dinitrophenylhy-
drazine at 365nm [32]. The concentration of carbonyl
groups was calculated on the basis of the absorption coeffi-
cient for this chromogen (a = 22 000M−1 cm−1); the results
are shown in μM.
Alpha 1-acid glycoprotein (AGP) determined using
Native PAGE, haptoglobin (Hp), and 3-nitrotyrosine (3-NT)
levels in plasma of rats was determined using SDS-PAGE
and Imunobloth methods with polyclonal antibody produced
in rabbit (Sigma-Aldrich, St. Louise, USA) and monoclonal
anti-3-nitrotyrosine antibody produced in mouse (Sigma-
Aldrich, St. Louise, USA) [33, 34].
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2.5. Determination of LDH. Total lactate dehydrogenase
(LDH) was determined by following the initial rate of pyru-
vate reduction to lactate [34]. The activity of LDH was
expressed in units per liter (U/L). Isoenzyme forms of LDH
(LDH1-LDH5) were detected by PAGE technique (Hoeffer
MiniVE, LKB, 2117, Bromma, Uppsala Sweden) using Tris-
glycine buffer and sodium-lactate as substrates in the pres-
ence of nitro blue tetrazolium chloride [35]. Band intensity
was measured densitometrically using TotalLab TL 120.
The relative activity of isoenzymes was shown in percentages.
2.6. Native Gel Electrophoresis of Plasma Proteins. Vertical
polyacrylamide gel electrophoresis at pH8.6 (alkaline-
PAGE) was carried out with Hoeffer miniVE cell (Amer-
sham, LKB, 2117, Bromma, Uppsala Sweden) at 120V and
room temperature for 2 h. The gel used (0.75mm thick)
consisted of 4.5% T staking gel and 8% T separation gel
(T% is an expression representing the concentration of acryl-
amide plus bisacrylamide in the gel). The electrode and
migration buffers consisted of 0.19M glycine and 0.024M
Tris at pH8.6. After electrophoresis, proteins were stained
using Coomassie blue 0.1% [36]. The band intensity was
measured using TotalLab TL120. Results were shown in per-
centages in relation to the total area. The albumin : globulin
ratio was calculated by dividing albumin content by the
sum of α-, β-, and γ-globulins.
2.7. Micronucleus Test. The preparation and staining of
bone marrow cells for the micronucleus test were performed
according to Schmid [37] and Mavournin et al. [38]. After 24
hours of treatment, the bone marrow cells were flushed out
with fetal calf serum, and the cells were suspended through
centrifugation, smeared, and stained with May-Grünwald
and Giemsa solution. A total of 1000 polychromatic eryth-
rocytes were scored for each animal at a magnification of
100x (oil immersion) using a microscope (Leica, Germany).
The PCE/NCE ratio was calculated to determine the cyto-
toxic effects of the adrenaline. All slides were coded and
scored blind.
2.8. Statistical Analysis. Statistical significance of differences
of all examined parameters was determined by means of
the ANOVA test followed by Dunnett test. Normality tests
were first performed for all groups using the d’Agostino-
Pearson omnibus test. Data were expressed as means ± stan
dard error (S.E.). Significance level was set at P < 0 05. Statis-
tical analysis was done using GraphPad Prism 7.0 Software,
CA, USA.
3. Results
Results of the analysis of total activity of Cu, Zn-SOD enzyme
in rats treated with adrenaline are shown in Figure 1. It was
observed that adrenaline treatment significantly decreased
(P < 0 001) the total enzyme activity by 26.09%, 38.09%,
and 69.97%, respectively, in relation to the control group.
Cyclophosphamide, as positive control, also reduces activity
of SOD (48.54%, P < 0 001). The decreased activities of
SOD biochemical assay were verified by the results of electro-
phoresis as shown in Figure 1(b).
Significant increase in CAT activity was identified at all
concentrations of adrenaline (Figure 2). The lowest con-
centration of adrenaline (0.75mg/kg) induced significant
increases (67.66± 5.83U/g Hb, P < 0 05) in activity of CAT
while the higher concentrations (1.5mg/kg and 3mg/kg) of
adrenaline induce a more evident increase (92.50± 9.35U/g
Hb and 95.65± 9.73U/g Hb, P < 0 001) compared to the con-
trol group (28.92± 1.83U/g Hb). Similarly, the activity of
CAT was significantly increased (P < 0 01) after treatment
with cyclophosphamide.
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Figure 1: SOD activity after treatment with adrenaline (a),
electrophoregram (b). Control group - C, groups treated with
adrenaline doses (A1-0.75mg/kg; A2-1.5 mg/kg; A3-3 mg/kg body
weight); group treated with cyclophosphamide (CP). Data are
expressed as means± SE. ∗∗∗P < 0 001 vs. control group.
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Figure 2: CAT activity after treatment with adrenaline. Control
group - C, groups treated with adrenaline doses (A1-0.75 mg/kg;
A2-1.5 mg/kg; A3-3 mg/kg body weight); groups treated with
cyclophosphamide (CP). Data are expressed as means± SE. ∗P <
0 05, ∗∗P < 0 01, ∗∗∗P < 0 001 vs. control group.
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In Figure 3, MDA levels after treatment with adrenaline
are shown. Adrenalin exerted a significant increase in a
dose-dependent manner (1.84-, 3.41-, 7.78-, and 5.29-fold,
P < 0 001) in MDA levels in rats compared to the untreated
group (Figure 3). Also, cyclophosphamide induced a signifi-
cant rise (P < 0 001) in MDA levels in respect to the control.
Results of the total LDH and its relative isoenzyme distri-
bution in rats treated with adrenaline are shown in Figures 4
and 5. There was clearly an increase (P < 0 001) in total activ-
ity of LDH in the group treated with all doses of adrenaline
compared to the control group. Cyclophosphamide induces
a less profound effect than the group treated with 3.5mg/kg
dose of adrenaline, but the total activity of LDH is also signif-
icantly increased (P < 0 001) in comparison to the control.
In Figure 5, it was observed that the LDH1 isoenzyme
shows an evident increase (P < 0 001) in rats treated with
adrenaline in respect to the control group. The lower but sta-
tistically significant effect (P < 0 05, P < 0 001) was evident in
the activity of LDH2 isoenzyme after adrenaline treatment
compared to the control group. Similarly, significant inten-
sity bands for LDH1 and LDH2 isoenzymes were noticed in
the group of rats treated with higher concentrations of adren-
aline. The activity of isoenzymes LDH1 and LDH2 was also
significantly increased (P < 0 01, P < 0 001) in rats treated
with cyclophosphamide.
The effect of adrenaline on PCC levels in rats is presented
in Figure 6. Compared to untreated rats, the significant eleva-
tion (P < 0 001) of PCC levels after treatment with all tested
doses of adrenaline was noticed (Figure 6). Rats treated with
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Figure 3: The level of MDA after treatment with adrenaline.
Control group - C, groups treated with adrenaline doses (A1-0.75
mg/kg; A2-1.5 mg/kg; A3-3 mg/kg body weight); group treated
with cyclophosphamide (CP). Data are expressed as means± SE.
∗∗∗P < 0 001 vs. control group.
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Figure 4: The total LDH level after treatment with adrenaline.
Control group - C, groups treated with adrenaline doses (A1-0.75
mg/kg; A2-1.5 mg/kg; A3-3 mg/kg body weight); groups treated
with cyclophosphamide (CP). Data are expressed as means± SE.
∗∗∗P < 0 001 vs. control group.
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Figure 5: Relative distribution of LDH1-LDH5 isoenzymes (a)
with electrophoretic profiles (b) after treatment with adrenaline.
Control group - C, groups treated with adrenaline doses (A1-0.75
mg/kg; A2-1.5 mg/kg; A3-3 mg/kg body weight); group treated
with cyclophosphamide (CP). Data are expressed as means± SE.
∗P < 0 05, ∗∗P < 0 01, ∗∗∗P < 0 001 vs. control group.
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Figure 6: The PCC levels after treatment with adrenaline.
Control group - C, groups treated with adrenaline doses (A1-0.75
mg/kg; A2-1.5 mg/kg; A3-3 mg/kg body weight); group treated
with cyclophosphamide (CP). Data are expressed as means± SE.
∗∗∗P < 0 001 vs. control group.
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cyclophosphamide also showed a significant rise (P < 0 001)
in PCC levels in comparison to control.
The level of NO2
− in rats after treatment with adrenaline
is shown in Figure 7. Adrenaline induced a significant eleva-
tion of NO2
− level in a dose-dependent manner. The highest
concentration (3mg/kg) of adrenaline induced the most dis-
tinct increases of NO2
− (P < 0 001) compared to the control
group. Positive control also induces a significant increment
in the level of NO2
− (P < 0 01).
The results of the electrophoretic distribution of plasma
proteins are shown in Figure 8, while the results of their rel-
ative distribution are given in Table 1.
In our studies, reduced albumin concentration in adren-
aline treatment has been demonstrated, and this decrease is
dose-dependent. Adrenaline has been shown to reduce albu-
min concentration by 5.81%, 16.09%, and 18.75% depending
on the dose level, while due to exposure to cyclophospha-
mide, the decrease of albumin is 9.62%. By comparing the
results of albumin level in all groups with the control group,
a statistically significant decrease in albumin was observed
in the adrenaline-treated group with 1.5 and 3.0mg/kg
(P < 0 01). A significant increase in α1 fraction (AGP,
α1-antitrypsin) versus the control group was observed in
groups treated with adrenaline in doses of 0.75mg/kg and
1.5mg/kg (P < 0 01), and 3mg/kg (P < 0 001), with increases
by 42.97%, 45.09%, and 252.79%, respectably. The α2-fraction
(Hp, ceruloplasmin, and α2-macroglobulin) was affected only
by adrenaline treatment indoses of 0.75mg/kg, 1.5mg/kg, and
3.0mg/kg and increases by 80.40% (P < 0 05), 150.67%
(P < 0 01), and 79.36% (P < 0 05). A significant decrease
(P < 0 05) of the β1-fraction (transferrin, haemopexin,
and β-lipoproteins) versus the control group was noticed
in groups treated with adrenaline in doses of 0.75mg/kg
(18.88%), 1.5mg/kg (27.63%), and 3mg/kg (19.32%). The
β2-fraction (fibrinogen, C3, and β2-microglobulin) in
groups treated with adrenaline was decreased by 27.78%
(dose 0.75mg/kg), 28.24% (1.5mg/kg), and 50.69% (3mg/
kg), which was significantly lower (P < 0 001) than in the
control group. In prealbumin and γ-globulin fractions, there
were no significant differences between treated and control
groups. A significant decrease (P < 0 05) in the ratio (A :G)
versus control group was noticed in groups treated with
adrenaline in doses of 1.5mg/kg and 3mg/kg.
The significant increase (P < 0 001) in AGP levels was
noticed in rats treated with adrenaline, especially at higher
doses (1.5mg/kg and 3mg/kg) in respect to the control group
(Figure 9). Related results of AGP levels on electropherogram
were also detected.
The effect of adrenaline treatment on level of haptoglobin
(Hp) in rats is presented in Figure 10. The significant differ-
ence (P < 0 01, P < 0 001) was observed in the level of Hp in
rats treated with 0.75mg/kg, 1.5mg/kg, and 3mg/kg of
adrenaline, versus the control group, respectively. These
results conformed with the electrophoretic profile.
The effect of adrenaline treatment on level of 3-
nitrotyrosine (3-NT) in rats is presented in Figure 11. A sig-
nificant difference (P < 0 001) was evident in the level of
nitrotyrosine in rats treated with all doses (1.5mg/kg and
3mg/kg) of adrenaline while a 0.75mg/kg dose of adrenaline
affects (P < 0 01) on the rise at the 3-NT level. In that man-
ner, the intensity of the band was most evident at 3mg/kg
of adrenaline in the electrophoretic profile.
The results of the micronucleus (MN) test in bone mar-
row of rats treated with adrenaline are shown in Table 2.
Adrenaline induced a significant increase (P < 0 001) in the
frequency of micronucleated polychromatic erythrocytes
(MNPCE) at higher concentrations (1.5mg/kg, 3mg/kg)
when compared with the negative control group. Also, signif-
icant and dose-dependent decreases in polychromatic eryth-
rocyte/normochromatic erythrocyte (PCE/NCE) ratio were
seen in higher doses of adrenaline (1.5mg/kg, 3mg/kg). As
expected, cyclophosphamide (60mg/kg) induced a signifi-
cant increase (P < 0 001) in MNPCE and decreases in the
PCE/NCE ratio in respect to the control.
4. Discussion
In the last few decades, researchers focus on detecting harmful
effects of chemical substances that are used as drugs in order to
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Figure 8: Representative electrophoregram of plasma proteins
with Native PAGE after treatment with adrenaline. Control
group- C, groups treated with adrenaline doses (A1-0.75mg/kg;
A2-1.5mg/kg; A3-3mg/kg body weight); groups treated with
cyclophosphamide (CP).
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Figure 7: The level of NO2- in rats after treatment with adrenaline.
Control group - C, groups treated with adrenaline doses (A1-0.75
mg/kg; A2-1.5 mg/kg; A3-3 mg/kg body weight); group treated
with cyclophosphamide (CP). Data are expressed as means± SE.
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protect human health. In this study, we investigated toxic
effects of adrenaline on Wistar rats using various parameters
(SOD, CAT, MDA, NO2
−, LDH, PCC, AGP, 3-NT, and
APP) and obtained results unequivocally indicate that
adrenaline at doses of 0.75mg/kg, 1.5mg/kg, and 3mg/kg
exerts oxidative and nitrative stress in rats.
In this study, SOD activity in erythrocytes was signifi-
cantly decreased while CAT activity was significantly
increased in rats treated with adrenaline compared to the
untreated group. SOD and CAT are the most important anti-
oxidant enzymes in the defense system against ROS [39].
These results may indicate that administration of adrenaline
in rats caused disruption in oxidant/antioxidant balance.
Superoxide anions generated in oxidative metabolism of
adrenaline may stimulate oxidation of adrenaline and thus
increase the amount of free radicals [11]. Decreased SOD
activity in treated rats indicated that excess level of
superoxide anions induced attenuation of SOD activity. On
the other hand, increased CAT activity found in rats treated
with adrenaline implies that CAT has an important protec-
tive role in removing free radicals produced in cells. This
assumption is supported by studies of Djelić et al. [10] and
Radakovic et al. [12] where catalase in cotreatment with
adrenaline reduced DNA damage mediated by free radicals
in human lymphocytes. Our results are in accordance with
the study of Pereira et al. [40] who reported that adrenaline
plays a role in the oxidative stress in the lymphoid organs
since adrenodemedullation affected the activities of antioxi-
dant enzymes.
We observed that the treatment with all doses of adrena-
line clearly increased MDA levels in rat erythrocytes. Polyun-
saturated fatty acids of the membrane are one of favored
oxidation targets of ROS due to its oxygen-rich environment
[41]. Our findings imply that adrenaline via free radicals
induces enhancement in lipid peroxidation. This is in agree-
ment with the study of Romana-Souza et al. [16] where treat-
ment with a high level of adrenaline resulted in a significant
Table 1: Relative distribution of proteins with Native PAGE after treatment with adrenaline.
Groups
Intensity, % (mean± SD)
Ratio (A : G)
Prealbumin Albumin α1- α2- β1- β2- γ-Globulins
C 2.66± 0.52 57.62± 3.80 5.19± 0.56 2.96± 1.62 15.89± 1.49 8.64± 0.79 7.04± 0.52 1.36± 0.22
A1 4.57± 0.57∗∗ 54.32± 1.07 7.42± 1.03∗∗ 5.34± 1.20∗ 12.89± 0.70∗ 6.24± 1.27∗ 9.78± 1.38∗ 1.20± 0.15
A2 3.66± 0.25 48.39± 3.72∗∗ 8.53± 0.66∗∗ 7.42± 1.36∗∗ 11.50± 0.85∗∗ 6.20± 1.28∗ 9.43± 1.23 0.94± 0.22∗
A3 2.05± 0.32 46.86± 2.54∗∗ 18.31± 3.01∗∗∗ 5.31± 1.32∗ 12.82± 1.52∗ 4.26± 2.57∗∗ 9.47± 1.56 0.88± 0.28∗
CP 3.69± 0.47∗ 52.07± 1.25 6.07± 1.73 2.17± 1.52 16.14± 0.83 9.66± 0.84∗∗ 9.11± 1.42 1.08± 0.23
∗P < 0 05, ∗∗P < 0 01, and ∗∗∗P < 0 001. C: control group, groups treated with adrenaline doses (A1, 0.75mg/kg; A2, 1.5 mg/kg; and A3, 3 mg/kg body weight);
CP: group treated with cyclophosphamide.
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Figure 9: Immunohistochemical detection of APG on Native
PAGE. The level of AGP (a) with electrophoregram (b) after
treatment with adrenaline. Control group - C, groups treated with
adrenaline doses (A1-0.75 mg/kg; A2-1.5 mg/kg; A3-3 mg/kg body
weight); group treated with cyclophoshamide (CP). Data are
expressed as means± SE. ∗∗P < 0 01, ∗∗∗P < 0 001 vs. control group.
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Figure 10: The level of haptoglobin (a) with electrophoregram (b)
after treatment with adrenaline. Control group - C, groups treated
with adrenaline doses (A1-0.75mg/kg; A2-1.5mg/kg; A3-3mg/
kg); group treated with cyclophosphamide (CP). Data are
expressed as means± SE. ∗∗P < 0 01, ∗∗∗P < 0 001 vs. control group.
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increment of lipid peroxidation in four days in murine der-
mal fibroblasts. An in vitro study of Bukowska et al. [42]
demonstrated increased lipid peroxidation in human periph-
eral blood mononuclear cells after treatment with catechol.
Increased lipid peroxidation indicates damage on cell mem-
branes caused by adrenaline. Analysis of total LDH activity
in this investigation confirms disturbance of the plasmamem-
brane integrity since increased LDH activity was found in rats
treated with adrenaline. In order to determine the type of
damaged tissue, LDH isoenzyme distribution was estimated.
A higher level of LDH1 and LDH2 isoenzymes was found in
the treated group which points on damage of cardiomyocytes
of adrenaline. A similar effect was revealed in rats treated with
cyclophosphamide. Our results suggest that cell membrane
damage in cardiac muscle is responsible for an increase in
LDH leakage which resulted as a consequence of oxidative
stress in rats exposed to adrenaline [43]. There is evidence
that cardiotoxicity may originate from adrenochrome, an oxi-
dative product of adrenaline [4]. It was demonstrated that
adrenochrome promotes redox cycling process with subse-
quent production of ROS [44]. This oxidative product of
adrenaline has been detected in the heart, skeletal muscle,
liver, and blood [9]. In this study, oxidative damage of pro-
teins has been manifested as an increased level of carbonyl
groups, in plasma of rats treated with adrenaline. As a conse-
quence of oxidative damage to proteins, their functions as
receptors, enzymes, or transport or structural proteins can
be disturbed [45]. Consistent with our results, Romana-
Souza et al. [16] reported increased levels of carbonylated pro-
teins in skin fibroblast cultures after treatment with adrena-
line. They indicate that adrenaline stimulates production of
ROS/RNS and increases protein oxidative damage consider-
ing that the detrimental effect was abolished when cells were
treated with inhibitors of free radicals. In addition, increased
protein carboxylation was detected in human blood cells after
treatment with catechol [42].
We observed that rats treated with all doses of adrenaline
induced significant elevation of nitrite oxide (NO) which is
manifested as a rise in the level of nitrite concentration
(NO2
−). Excessive NO synthesis often causes myocardium
damage and loss of contractile function [46]. The toxicity of
NO is reflected to its ability to react with superoxide to pro-
duce potent oxidant peroxynitrite (ONOO−) [47]. Therefore,
this result points on nitrosative stress in rats treated with
adrenaline. Namely, ONOO−may spontaneously decompose
to yield NO2
− and high reactive radical •OH. Forming
ONOO− can take part of lipid peroxidation in reaction with
unsaturated fatty acid-containing liposomes. In addition,
ONOO− may influence on protein participation in signal
transduction mechanisms [48]. It was found that high con-
centrations of ONOO− often lead to necrotic-type cell death
[49]. Supportive evidence about the presence of nitrosative
stress is revealed by our findings that an increase in the level
of 3-NT was detected in the adrenaline-treated group. Con-
sistent with our result is the study of Romana-Souza et al.
[16] who reported an increased level of nitrotyrosine in
mouse skin after treatment with a high level of adrenaline.
The mechanism of protein tyrosine nitration in biological
systems has been well described [50]. Nitrotyrosine forma-
tion has been observed in various cardiovascular diseases
[50–52]. An increased level of 3-NT may cause alternation
of protein function, protein-protein interactions, and cell
signaling [50, 53, 54]. Also, one of the consequences of adren-
aline application is the acute phase response, which we dem-
onstrated by evaluating APPs. One of the most important
metabolic changes during the acute phase is the production
of APPs which are released from the liver into the plasma
[55]. This occurs within a few hours, and these proteins
remain elevated as long as the inflammatory stimulus per-
sists, making them perfect indicators of inflammation or
injury, and useful for predicting the outcome of disease.
Their only flaw is that they are poorly specific. APPs have
been widely used in human and veterinary medicine as
biomarkers of diseases, inflammatory processes, and various
infections [56, 57]. Classification of APPs can be done
according to the magnitude of the increase (positive APPs)
or decrease (negative APPs) in their serum concentrations
during the acute phase response [58]. Some of the APPs
(α1-antitrypsin, and α2-macroglobulin) have antiprotease
activity designed to inhibit phagocyte proteases and to mini-
mize tissue damage. Others (α1-acid glycoprotein) have anti-
bacterial or scavenging activity (haptoglobin, serum amyloid
A, and C-reactive protein), by binding metabolites released
from cellular degradation so they cannot be utilized by path-
ogen. Albumin, as a negative APP, is a major source of amino
acids and is responsible for about 75% of the osmotic pres-
sure of plasma. In this study, it has been shown that adrena-
line reduced the albumin concentration by a dose-dependent
level and also exposure to cyclophosphamide led to a
decrease of albumin. Adrenaline causes an increased flux of
free radicals, which can be due to the oxidation of thiol
groups and the formation of albumin dimers or polymers,
and consequently the reduction in osmotic pressure accurse.
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Figure 11: The level of nitrotyrosine (a) with electrophoregram (b)
after treatment with adrenaline. Control group - C, groups treated
with adrenaline doses (A1-0.75 mg/kg; A2-1.5 mg/kg; A3-3 mg/kg
body weight); group treated with cyclophosphamide (CP). Data are
expressed as means± SE. ∗∗P < 0 01, ∗∗∗P < 0 001 vs. control group.
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The effect of the acute phase protein AGP in rats
exposed to adrenaline was also estimated. A significant
dose-dependent elevation in AGP following adrenalin treat-
ment was observed. AGP is a positive APP with a normal
concentration in the human plasma at 0.6–1.2mg/mL [59].
The plasma concentration of AGP can increase from 2- to
10-fold when influenced by various factors, such as stress,
inflammation drugs (phenobarbitone and rifampicin), burns,
infections, and pregnancy. AGP possesses immunomodula-
tory activities and modulates neutrophil chemotactic migra-
tion and superoxide generation [60]. AGP significantly
suppresses synthesis of IL-2, proliferation of lymphocytes,
and platelet aggregation [61]. It has been shown that AGP
protects neutrophil generation of ROS probably due to bind-
ing of free radicals [62]. AGP can bind to a number of metab-
olites such as heparin, histamine and serotonin, steroids,
catecholamines, and pharmacological compounds. Increased
AGP may affect pharmacokinetics by reducing the concen-
tration of free drugs, by binding to the metabolically active
fraction of the drug. Matsumoto et al. [63] reported that
human AGP at physiological concentrations protects eryth-
rocytes from H2O2. On the basis of the above-mentioned,
we assume that the AGP level increases in response to oxida-
tive stress after treatment with adrenaline. In this study, we
detected an increased Hp level in rats treated with higher
doses of adrenaline (1.5 and 3mg/kg). Haptoglobin (Hp) is
a positive acute-phase glycoprotein classified in α2 fraction
together with fibrinogen and α-globulins with antiprotease
activity [64]. Hp has a pronounced anti-inflammatory action,
because of its ability to bind to heme of haemoglobin, form-
ing an Hp-Hb complex. By forming this complex, Hp pre-
vents the promotion of free radicals and its accumulation in
endothelial cells which is catalysed by heme. Free Hb has
the ability to catalyse the formation of hydroxyl radicals from
H2O2. By binding to neutrophils, Hp may inhibit NADPH
oxidase activation and therefore the production of reactive
forms of oxygen associated with inflammation. The Hp-Hb
complex, by removing free Hb, prevents renal injury that
may occur when free Hb passes through the glomerular filter
[65]. There is a great variability in antioxidant capacity,
depending on Hp polymorphism, so individuals with Hp2-
2 have a lower antioxidant capacity [65]. The Hp-Hb com-
plex also binds nitric oxide or nitrogen monoxide (NO)
[66]. This action is also phenotype-dependent. Due to its
longer half-life, the Hp2-2/Hb complex scavenges more
NO than the Hp1-1/Hb complex does [67, 68]. Haptoglo-
bin can also modulate the immune response by binding to
receptors on immune cells. Glucocorticoids and catechol-
amines activate haptoglobin synthesis whereas insulin exerts
an opposite action. Since increased levels of extracellular Hb
can occur due to impaired membrane integrity, we assumed
that Hp scavenges free Hb as a result of lipid peroxidation.
This fact coincides with our results of MDA analysis and
leads to a conclusion that an elevated Hp level has a pro-
tective response to adrenaline-induced oxidative stress.
Our findings unequivocally point that adrenaline induces
an acute phase response. Although the APPs are a signifi-
cant marker of inflammation and/or infection, it seems
that these results give a new linkage between APPs and
noninflammatory stress.
The possible genotoxicity of adrenaline was evaluated by
a micronucleus test in bone marrow cells of rats. The results
indicate that adrenaline expresses a genotoxic effect at higher
concentrations (1.5 and 3mg/kg) since it caused a significant
induction of MN in the bone marrow of rats. This result is in
compliance with the study of McGregor et al. [69] in which
the adrenaline exhibited a mutagenic effect on mouse
L5178Y lymphoma cells. In the Comet assay, adrenaline
induced DNA damage in 3T3 cells of rats [6]. In our work,
tested catecholamine (1.5 and 3mg/kg) decreased the PCE/
NCE ratio indicating its cytotoxicity in bone marrow.
Muthuraman et al. [70] showed that adrenaline possessed a
cytotoxic effect and affects DNA fragmentation in a dose-
dependent manner in MDCK cells.
Several studies have implicated involvement of free
radicals in the genotoxic action of adrenaline [12, 71].
Antioxidant enzymes CAT and SOD are the integral part
of antioxidant defense mechanisms and have a consider-
able importance since they are involved in protection from
free radicals. We assume that the antioxidants respond to
oxidative stress caused by adrenaline since significant
changes in the CAT and SOD activity in treated rats were
detected. Martıńez et al. [72] have classified catecholamines
as potent oxidative mutagens. It has been suggested that
catecholamine generates free radicals by autooxidation
and redox cycling [44]. ROS have the ability to induce
various types of DNA damage such as double-strand
breaks (DSB), and this type of DNA damage is considered
as a main contributor to MN induction [73]. We suggest
that the increased induction of MN in the bone marrow
of rats is a result of increased production of free radicals
produced by oxidative metabolism of adrenaline. So, it
should be expected that antioxidants could protect cells
from toxic effects of adrenaline.
Table 2: The frequency of micronuclei in bone marrow of Wistar rats treated with different doses of adrenaline.
Treatment Treatment time (h) Doses mg/kg Total cell number MNPCE (%) PCE (%)
Negative control 24 0 5000 0.80± 0.37 49.24± 0.02
Adrenaline
24 0.75 5000 1.20± 0.49 47.92± 0.21
24 1.5 5000 2.80± 0.37∗ 46.40± 0.44∗∗
24 3 5000 5.40± 0.24∗ 43.43± 1.19∗∗∗
Cyclophosphamide 24 60 5000 14.40± 0.40∗ 47.94± 0.38∗∗∗
Data are expressed as means ± SE. ∗∗P < 0 01 and ∗∗∗P < 0 001 vs. the control group.
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5. Conclusion
In summary, our results show that adrenaline induces oxi-
dative and nitrative stress in Wistar rats, accompanied by
changes in the activity of antioxidant enzymes, increased
damage to lipids and proteins, increased level of NO2
−
and nitrotyrosine derivate, damage of cardiomyocytes, and
genotoxic damage. Also, adrenaline exerts acute-phase
response through increased level of AGP and Hp and
decreased level of serum albumin level. Therefore, obtained
results may contribute to better understanding of adrenaline
toxicity with aims at preventing its harmful effects.
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